🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A new corridor for lepto metastases, the integrin α6 and the GDNF signaling axis to bypass BBB: new therapeutic targets against breast cancer LM? doi.org/10.1126/scienc…

Mechanisms of resistance and impact of D-2HG in impairing microglia activation following IDH inhibitors...trials in combination with ICIs are awaited EANO #eano2024

Great overview on correlations of molecular signatures, grading, locations, and outcomes in skull based tumors EANO #eano2024

Dramatic response after BRAF/MEK inhibitors in BRAF mutated craniopharyngioma...many questions still opened, including if cfDNA is feasible to monitor response EANO #EANO2024

a novel special issue on "New Perspectives in the Management of Central Nervous System (CNS) Tumors" for submitting papers, especially for youngster researchers and investigators mdpi.com/journal/cancer…

Thanks GEINO and Estela Pineda for the wonderful opportunity to talk on ONC-201 Chimerix, Inc. in K27M mutated midline gliomas, looking forward to further collaboration 🇪🇦🤝🇮🇹

"Never give up, focus, and give 100%. It's not about us. It's about the patients and their loved ones. It's about them." - Mitchel Berger #SNO2024 #ScientificMeeting

Great initiative of RANO group on systematizing liquid biopsy in Neuro-Oncology presented by Riccardo Soffietti at #SNO2024 - looking forward to the publication!

Amazing Priya Kumthekar summarizes CSF liquid biopsy for diagnosis and novel CSF delivery tools for treatment of LM SNO #SNO2024

📢Highlights from SNO 2024 The SNO 2024 conference in Houston highlighted groundbreaking advancements in brain cancer research, with discussions on molecular diagnostics, novel treatments, and new collaborations in neuro-oncology. Ashley Love Sumrall, MD, FACP, FASCO SNO Keri Martinowich

World Cancer Day...focus on brain metastases 🧠 SOCIETÀ ITALIANA DI NEUROLOGIA #braintumor

A groundbreaking case study on upfront neoadjuvant ICIs administration (a-PD1, a-CTLA-4,a-LAG3 before GBM surgery, with robust anti tumor immune activation andcextended survival. A new clinical trial (NCT06816927) is planned nature.com/articles/s4159…

DESTINY-Breast09 press release highlights a potential novel 1st line therapy in MBC over the standard of care...

👀👀 in a few hours 👀👀 #ASCO25 #DB09

HER2 IHC 3+ testing in 65,000+ solid tumors shows a 3.1% positivity rate Most common➡️Bladder (13.9%), uterine serous (13.6%), GEJ (12.1%). Least common➡️Glioma, sarcoma, SCLC(0%) 📌Bx and resection samples yield largely similar HER2 positivity rates jamanetwork.com/journals/jamao…

A new study identifies a novel subset of mast cells that cross-present tumor antigens in triple-negative #breastcancer — and a pilot trial shows how these can be exploited in immunotherapy strategies. News & Views from Ignacio Melero et al Clínica Universidad de Navarra nature.com/articles/s4159…